NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:

  • Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MA
  • Jefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London
  • 7th Annual Evercore HealthCONx Conference on December 4 at 10:50 a.m. ET in Coral Gables, FL

Live webcasts of the Company's presentations at these three conferences may be accessed under "News and Events” in the Investors section of the Dianthus Therapeutics website.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact

Jennifer Davis Ruff

Dianthus Therapeutics

[email protected]